Generic paradigms often offer ambiguous solutions without addressing underlying health issues. Relying solely on stacking drugs to manage symptoms can lead to unresolved health problems that persist and eventually lead to serious conditions like heart attacks. While medications can help manage dysfunction, understanding the risk-reward profile of each drug is crucial. Lowering cholesterol or managing symptoms does not equate to solving health issues. Some newer drugs may lack comprehensive information to fully assess their benefits and risks.
Today, Paul and Mike unpack their opinions about lipids. They talk about true risk for cardiovascular disease, primary versus secondary prevention, lipid lowering drugs, and share their thoughts on a recent podcast episode with Peter Attia.
*Produced by Mountain Valley Media
00:06:08 Blood markers & imaging techniques of metabolic function
00:14:38 Gene mutations
00:20:28 LDL & Plaque burden
00:27:23 Money in statins
00:31:38 Downsides of lowering LDL
01:21:23 The downsides of popular cholesterol lowering drugs
01:41:07 Should we fear heart attacks?
01:45:23 PCSK9 Inhibitors
01:52:43 Risk profile of Statins
01:53:02 Risk vs. reward of Ezetimibe
02:04:02 Primary vs. secondary prevention
Resources:
Debunking Sugar Claims: What Dr. Lustig Got Wrong On The Huberman Podcast:
https://www.youtube.com/watch?v=JcEmSgbMfco&t=2933s
Work With Mike: https://mikefave.com/